Among molecular subtypes, HER-2-positive patients (40.0% of the cohort) had the highest pCR rate (73.0%, 16/22), followed by triple-negative breast cancer (TNBC) patients (15.0% of the cohort, 50.0%, 4/8). Here, ERBB2 is linked to triple-negative breast carcinoma.